<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35473737</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>26</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Therapies for Long COVID in non-hospitalised individuals: from symptoms, patient-reported outcomes and immunology to targeted therapies (The TLC Study).</ArticleTitle><Pagination><StartPage>e060413</StartPage><MedlinePgn>e060413</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e060413</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2021-060413</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Individuals with COVID-19 frequently experience symptoms and impaired quality of life beyond 4-12 weeks, commonly referred to as Long COVID. Whether Long COVID is one or several distinct syndromes is unknown. Establishing the evidence base for appropriate therapies is needed. We aim to evaluate the symptom burden and underlying pathophysiology of Long COVID syndromes in non-hospitalised individuals and evaluate potential therapies.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">A cohort of 4000 non-hospitalised individuals with a past COVID-19 diagnosis and 1000 matched controls will be selected from anonymised primary care records from the Clinical Practice Research Datalink, and invited by their general practitioners to participate on a digital platform (Atom5). Individuals will report symptoms, quality of life, work capability and patient-reported outcome measures. Data will be collected monthly for 1&#x2009;year.Statistical clustering methods will be used to identify distinct Long COVID-19 symptom clusters. Individuals from the four most prevalent clusters and two control groups will be invited to participate in the BioWear substudy which will further phenotype Long COVID symptom clusters by measurement of immunological parameters and actigraphy.We will review existing evidence on interventions for postviral syndromes and Long COVID to map and prioritise interventions for each newly characterised Long COVID syndrome. Recommendations will be made using the cumulative evidence in an expert consensus workshop. A virtual supportive intervention will be coproduced with patients and health service providers for future evaluation.Individuals with lived experience of Long COVID will be involved throughout this programme through a patient and public involvement group.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">Ethical approval was obtained from the Solihull Research Ethics Committee, West Midlands (21/WM/0203). Research findings will be presented at international conferences, in peer-reviewed journals, to Long COVID patient support groups and to policymakers.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER">1567490.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haroon</LastName><ForeName>Shamil</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0096-1413</Identifier><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK s.haroon@bham.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nirantharakumar</LastName><ForeName>Krishnarajah</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6816-1279</Identifier><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Research UK (HDR UK) Midlands, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><Identifier Source="ORCID">0000-0001-5656-1198</Identifier><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research (NIHR) Applied Research Centre West Midlands, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramanian</LastName><ForeName>Anuradhaa</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8875-7363</Identifier><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aiyegbusi</LastName><ForeName>Olalekan Lee</ForeName><Initials>OL</Initials><Identifier Source="ORCID">0000-0001-9122-8251</Identifier><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute for Health Research (NIHR) Applied Research Centre West Midlands, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Elin Haf</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Aparito Ltd, Wrexham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myles</LastName><ForeName>Puja</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Grace</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-9783-9413</Identifier><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandan</LastName><ForeName>Joht Singh</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMullan</LastName><ForeName>Christel</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0878-1513</Identifier><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lord</LastName><ForeName>Janet</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1030-6786</Identifier><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wraith</LastName><ForeName>David C</ForeName><Initials>DC</Initials><Identifier Source="ORCID">0000-0003-2147-5614</Identifier><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGee</LastName><ForeName>Kirsty</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-5593-4252</Identifier><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denniston</LastName><ForeName>Alastair K</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0001-7849-0087</Identifier><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taverner</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Louise J</ForeName><Initials>LJ</Initials><Identifier Source="ORCID">0000-0001-8492-0020</Identifier><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sapey</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3454-5482</Identifier><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gkoutos</LastName><ForeName>George</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-2061-091X</Identifier><AffiliationInfo><Affiliation>Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gokhale</LastName><ForeName>Krishna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leggett</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Clinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iles</LastName><ForeName>Clare</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Aparito Ltd, Wrexham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McNamara</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Aparito Ltd, Wrexham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bamford</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Tom</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9277-5214</Identifier><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zemedikun</LastName><ForeName>Dawit T</ForeName><Initials>DT</Initials><Identifier Source="ORCID">0000-0003-3642-0456</Identifier><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Patient Partners, Not applicable, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marwaha</LastName><ForeName>Steven</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0303-9942</Identifier><AffiliationInfo><Affiliation>Institute for Mental Health, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simms-Williams</LastName><ForeName>Nikita</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4926-1995</Identifier><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Kirsty</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9403-1593</Identifier><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Patient Partners, Not applicable, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camaradou</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Patient Partners, Not applicable, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saint-Cricq</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Patient Partners, Not applicable, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Sumita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Patient Partners, Not applicable, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alder</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Patient Partners, Not applicable, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanton</LastName><ForeName>David E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Patient Partners, Not applicable, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agyen</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Patient Partners, Not applicable, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baber</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Patient Partners, Not applicable, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blaize</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Patient Partners, Not applicable, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvert</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1856-837X</Identifier><AffiliationInfo><Affiliation>Institute of Applied Health Research, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health Data Research UK (HDR UK) Midlands, Birmingham, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_19005</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_21015</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_20050</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/P021220/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="N">Patient Reported Outcome Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">immunology</Keyword><Keyword MajorTopicYN="N">public health</Keyword><Keyword MajorTopicYN="N">therapeutics</Keyword></KeywordList><CoiStatement>Competing interests: MC is Director of the Birmingham Health Partners Centre for Regulatory Science and Innovation, Director of the Centre for the Centre for Patient Reported Outcomes Research and is a National Institute for Health Research (NIHR) Senior Investigator. MC receives funding from the NIHR Birmingham Biomedical Research Centre (BRC), the NIHR Surgical Reconstruction and Microbiology Research Centre and NIHR ARC West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, UCB Pharma, Janssen, GlaxoSmithKline (GSK) and Gilead. MC has received personal fees from Astellas, Aparito, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. SEH is supported by the NIHR Applied Research Centre (ARC), West Midlands at the University of Birmingham. SEH has received personal fees from Cochlear and Aparito outside the submitted work. OLA receives funding from the NIHR Birmingham BRC, NIHR ARC, West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation, Innovate UK (part of UK Research and Innovation), Gilead Sciences and Janssen Pharmaceuticals. OLA declares personal fees from Gilead Sciences, GSK and Merck outside the submitted work. CM receives funding from the NIHR Surgical Reconstruction and Microbiology Research Centre, Innovate UK, and has received personal fees from Aparito outside the submitted work. PM, TW, CI and EL are employees of Clinical Practice Research Datalink (CPRD), the data custodians for CPRD Aurum. CPRD is jointly sponsored by the UK government&#x2019;s Medicines and Healthcare Products Regulatory Agency and the NIHR. As a not-for-profit UK government body, CPRD seeks to recoup the cost of delivering its research services to academic, industry and government researchers through research user license fees. JC is a lay member on the UK NICE COVID expert panel, a citizen partner to the COVID END Evidence Synthesis Network, PPI lead on the NIHR CICADA ME Study, patient representative at the EAN European Neurology Autonomic Nervous Systems Disorders Working Group, a member of the MRC/UKRI Advanced Pain Discovery Platform and external board member of Plymouth Institute of Health. She also reports contracts with GSK and Medable.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>27</Day><Hour>5</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35473737</ArticleId><ArticleId IdType="pmc">PMC9044550</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2021-060413</ArticleId><ArticleId IdType="pii">bmjopen-2021-060413</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>GOV.UK . Cases in United Kingdom, 2021. Available: https://coronavirus.data.gov.uk/details/cases [Accessed 19 Oct 2021].</Citation></Reference><Reference><Citation>Center for systems science and engineering (CSSE) at John Hopkins University. COVID-19 MAP, 2021. Available: https://coronavirus.jhu.edu/map.html [Accessed 19 Oct 2021].</Citation></Reference><Reference><Citation>GOV.UK . Deaths in United Kingdom, 2021. Available: https://coronavirus.data.gov.uk/details/deaths [Accessed 19 Oct 2021].</Citation></Reference><Reference><Citation>GOV.UK . Healthcare in United Kingdom, 2021. Available: https://coronavirus.data.gov.uk/details/healthcare [Accessed 19 Oct 2021].</Citation></Reference><Reference><Citation>Aiyegbusi OL, Hughes SE, Turner G, et al. . Symptoms, complications and management of long COVID: a review. J R Soc Med 2021;114:428&#x2013;42. 10.1177/01410768211032850</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768211032850</ArticleId><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A'Court C, et al. . Management of post-acute covid-19 in primary care. BMJ 2020;370:m3026. 10.1136/bmj.m3026</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence . COVID-19 rapid guideline: managing the long-term effects of COVID-19, 2020. Available: https://www.nice.org.uk/guidance/NG188 [Accessed 19 Oct 2021].</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol 2020;16:413&#x2013;4. 10.1038/s41584-020-0448-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0448-7</ArticleId><ArticleId IdType="pmc">PMC7271827</ArticleId><ArticleId IdType="pubmed">32499548</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau-Hyam M. Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people. medRxiv. 10.1101/2021.06.28.21259452</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.28.21259452</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics . Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 April 2021, 2021. Available: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021 [Accessed 28 Oct 2021].</Citation></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T. Attributes and predictors of long COVID. Nat Med 2021:1&#x2013;6. 10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health Research . NIHR themed review: living with Covid19 2020. 10.3310/THEMEDREVIEW_41169</Citation><ArticleIdList><ArticleId IdType="doi">10.3310/THEMEDREVIEW_41169</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxwell E, Poole R. NIHR themed review: Living with Covid19 - Second review. 10.3310/themedreview_45225</Citation><ArticleIdList><ArticleId IdType="doi">10.3310/themedreview_45225</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Long covid could be four different syndromes, review suggests. BMJ 2020;371:m3981. 10.1136/bmj.m3981</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3981</ArticleId><ArticleId IdType="pubmed">33055076</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi N. Long covid: how to define it and how to manage it. BMJ 2020;370:m3489. 10.1136/bmj.m3489</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3489</ArticleId><ArticleId IdType="pubmed">32895219</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Lee KA, Lochlainn MN, et al. . Symptom clusters in COVID-19: a potential clinical prediction tool from the COVID symptom study APP. Sci Adv 2021;7. 10.1126/sciadv.abd4177. [Epub ahead of print: 19 03 2021].</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abd4177</ArticleId><ArticleId IdType="pmc">PMC7978420</ArticleId><ArticleId IdType="pubmed">33741586</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med 2021;27:28&#x2013;33. 10.1038/s41591-020-01202-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01202-8</ArticleId><ArticleId IdType="pubmed">33442016</ArticleId></ArticleIdList></Reference><Reference><Citation>British Society for Immunology . Long-Term immunological health consequences of COVID-19, 2020. Available: https://www.immunology.org/sites/default/files/BSI_Briefing_Note_August_2020_FINAL.pdf [Accessed 19 Oct 2021].</Citation></Reference><Reference><Citation>Nehme J, Borghesan M, Mackedenski S, et al. . Cellular senescence as a potential mediator of COVID-19 severity in the elderly. Aging Cell 2020;19:e13237. 10.1111/acel.13237</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13237</ArticleId><ArticleId IdType="pmc">PMC7576296</ArticleId><ArticleId IdType="pubmed">32955770</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondelli V, Pariante CM. What can neuroimmunology teach us about the symptoms of long-COVID? Oxf Open Immunol 2021;2:iqab004. 10.1093/oxfimm/iqab004</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfimm/iqab004</ArticleId><ArticleId IdType="pmc">PMC7928677</ArticleId><ArticleId IdType="pubmed">34192271</ArticleId></ArticleIdList></Reference><Reference><Citation>Recovery . Welcome &#x2014; recovery trial, 2020. Available: https://www.recoverytrial.net/ [Accessed 19 Oct 2021].</Citation></Reference><Reference><Citation>PHOSP . Home - PHOSP-COVID, 2020. Available: https://phosp.org/ [Accessed 19 Oct 2021].</Citation></Reference><Reference><Citation>PRINCIPLE . Help find treatments for COVID-19 from home, 2021. Available: https://www.principletrial.org/ [Accessed 2 Nov 2021].</Citation></Reference><Reference><Citation>NIHR . STIMULATE-ICP: understanding long COVID to improve diagnosis, treatment and care, 2020. Available: https://www.arc-nt.nihr.ac.uk/research/projects/stimulate-icp-improving-diagnosis-treatment-and-care-of-long-covid/ [Accessed 2 Nov 2021].</Citation></Reference><Reference><Citation>LongCovidSOS, 2021. Available: https://www.longcovidsos.org/ [Accessed 22 Oct 2021].</Citation></Reference><Reference><Citation>Wolf A, Dedman D, Campbell J, et al. . Data resource profile: clinical practice research Datalink (CPRD) aurum. Int J Epidemiol 2019;48:1740&#x2013;1740g. 10.1093/ije/dyz034</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyz034</ArticleId><ArticleId IdType="pmc">PMC6929522</ArticleId><ArticleId IdType="pubmed">30859197</ArticleId></ArticleIdList></Reference><Reference><Citation>Gokhale KM, Chandan JS, Toulis K, et al. . Data extraction for epidemiological research (Dexter): a novel tool for automated clinical epidemiology studies. Eur J Epidemiol 2021;36:165&#x2013;78. 10.1007/s10654-020-00677-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-020-00677-6</ArticleId><ArticleId IdType="pmc">PMC7987616</ArticleId><ArticleId IdType="pubmed">32856160</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani R, Walther G, Hastie T. Estimating the number of clusters in a data set via the gap statistic. J R Stat Soc Ser B (Statistical Methodol 2001;63:411&#x2013;23. 10.1111/1467-9868.00293</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1467-9868.00293</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseeuw PJ. Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. J Comput Appl Math 1987;20:53&#x2013;65. 10.1016/0377-0427(87)90125-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0377-0427(87)90125-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalmaijer E, Nord CL, Astle D. Statistical power for cluster analysis. ArXiv 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9158113</ArticleId><ArticleId IdType="pubmed">35641905</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroon S, Subramanian A, Gkoutos G. Long COVID in non-hospitalised individuals: symptoms, risk factors and syndromes. CPRD, 2021. Available: https://cprd.com/protocol/long-covid-non-hospitalised-individuals-symptoms-risk-factors-and-syndromes [Accessed 19 Oct 2021].</Citation></Reference><Reference><Citation>Curtis L, Burns A. Unit costs of health and social care 2020, personal social services research unit. Canterbury, 2020.</Citation></Reference><Reference><Citation>NHS . National cost collection for the NHS, 2020. Available: https://www.england.nhs.uk/national-cost-collection/ [Accessed 26 Oct 2021].</Citation></Reference><Reference><Citation>Jo C. Cost-Of-Illness studies: concepts, scopes, and methods. Clin Mol Hepatol 2014;20:327. 10.3350/cmh.2014.20.4.327</Citation><ArticleIdList><ArticleId IdType="doi">10.3350/cmh.2014.20.4.327</ArticleId><ArticleId IdType="pmc">PMC4278062</ArticleId><ArticleId IdType="pubmed">25548737</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi H-J, Lee E-W. Methodology of estimating socioeconomic burden of disease using National health insurance (NHI) data. Eval Heal Serv.</Citation></Reference><Reference><Citation>James Lind Alliance . Chapter 8: final priority setting, 2020. Available: https://www.jla.nihr.ac.uk/jla-guidebook/chapter-8/final-priority-setting.htm [Accessed 19 Oct 2021].</Citation></Reference><Reference><Citation>Michie S, Atkins L, West R. The behaviour change wheel: a guide to designing interventions. London: Silverback, 2014. http://www.behaviourchangewheel.com/</Citation></Reference><Reference><Citation>Carter S, Steynor A, Vincent K. A manual for co-production in African weather and climate services: home. Cape town, 2019. Available: https://futureclimateafrica.org/coproduction-manual/ [Accessed 19 Oct 2021].</Citation></Reference><Reference><Citation>Staniszewska S, Brett J, Simera I. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. BMJ 2017;358:3453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5539518</ArticleId><ArticleId IdType="pubmed">28768629</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health Research . NIHR include guidance (General), 2020. Available: https://www.learningforinvolvement.org.uk/?opportunity=nihr-include-guidance-general [Accessed 19 Oct 2021].</Citation></Reference><Reference><Citation>National Institute for Health Research, Chief Scientist Office, Health and Care Research Wales . Uk standards for public involvement, 2019. Available: https://sites.google.com/nihr.ac.uk/pi-standards/standards?authuser=0 [Accessed 2 Nov 2021].</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>